Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. - Dataset (ID:20270)
Download: Excel (XLSX), Comma-separated (CSV)
| Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | GR50 lower quartile | GR50 median | GR50 upper quartile | GRmax lower quartile | GRmax median | GRmax upper quartile | GRinf lower quartile | GRinf median | GRinf upper quartile | Hill Coefficient lower quartile | Hill Coefficient median | Hill Coefficient upper quartile | GR_AOC lower quartile | GR_AOC median | GR_AOC upper quartile | GEC50 lower quartile | GEC50 median | GEC50 upper quartile |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selumetinib | MEK | MAPK | 3.4703 | 100.0000 | 100.0000 | 0.2888 | 0.6993 | 0.8618 | 0.1384 | 0.6524 | 0.8687 | 0.0000 | 0.4990 | 0.9393 | 0.0510 | 0.1233 | 0.3040 | 0.3246 | 2.6951 | 100.0000 | |
| Fascaplysin | CDK4 | CDK | 0.1734 | 0.2805 | 0.3987 | -0.9809 | -0.9546 | -0.8701 | -0.9898 | -0.9538 | -0.8570 | 1.9348 | 2.3235 | 2.8230 | 0.5843 | 0.6643 | 0.7626 | 0.3281 | 0.4110 | 0.6267 | |
| ICRF-193 | TOP2 | TOP | 8.5852 | 100.0000 | 100.0000 | 0.3561 | 0.5910 | 0.6710 | 0.2252 | 0.4446 | 0.6698 | 0.1440 | 0.6745 | 1.5658 | 0.1152 | 0.1622 | 0.2393 | 0.3708 | 3.7956 | 100.0000 | |
| Epirubicin | TOP2 | TOP | 0.2120 | 0.3019 | 0.4930 | -0.9915 | -0.9463 | -0.8152 | -0.8492 | -0.7437 | -0.6556 | 0.9325 | 1.4047 | 2.1457 | 0.6134 | 0.7438 | 0.8467 | 0.3985 | 0.6015 | 1.3650 | |
| TCS 2312 | CHK1 | CHK | 0.3474 | 0.6156 | 0.9604 | -0.8358 | -0.6163 | -0.3941 | -0.8432 | -0.6104 | -0.3951 | 1.4081 | 2.0751 | 2.9131 | 0.3572 | 0.4368 | 0.5565 | 0.6031 | 1.0589 | 1.5099 | |
| Z-Leu-Leu-Norvalinal | Proteasome | Proteasome | 0.4036 | 0.5478 | 1.0248 | -0.8567 | -0.7928 | -0.6682 | -0.8570 | -0.7958 | -0.6543 | 1.7769 | 2.1873 | 3.5139 | 0.5265 | 0.6392 | 0.6811 | 0.6073 | 0.7378 | 1.6091 | |
| XRP44X | ELK3 | MAPK | 0.7816 | 1.1482 | 1.8976 | -0.2021 | 0.0602 | 0.2789 | -0.1369 | 0.0575 | 0.2934 | 1.8769 | 3.3942 | 4.9998 | 0.2905 | 0.3686 | 0.4637 | 0.6561 | 1.0109 | 1.3678 | |
| ZM-447439 | AURK | AURK | 3.5193 | 19.1991 | 100.0000 | -0.0403 | 0.4141 | 0.5578 | -0.1176 | 0.3301 | 0.5652 | 0.5578 | 1.0337 | 2.9596 | 0.1428 | 0.2012 | 0.3024 | 0.6732 | 2.5837 | 16.4745 | |
| Pemetrexed | TYMS/DHFR/GARFT | TYMS | 70.1583 | 100.0000 | 100.0000 | 0.5012 | 0.6411 | 0.8577 | 0.5144 | 0.6941 | 0.8649 | 0.0000 | 0.7943 | 1.8547 | 0.0614 | 0.1870 | 0.3357 | 0.9463 | 34.1832 | 100.0000 | |
| Afatinib | EGFR/HER2 | ErbB | 0.1253 | 1.5517 | 2.4757 | -0.9553 | -0.9200 | -0.8460 | -1.0000 | -1.0000 | -0.9391 | 0.5080 | 1.0283 | 1.7263 | 0.4620 | 0.5435 | 0.6679 | 1.1116 | 3.3143 | 4.9447 | |
| Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.2491 | 0.7096 | 1.5478 | -0.9565 | -0.8762 | -0.7290 | -1.0000 | -1.0000 | -0.9202 | 0.6212 | 0.8572 | 1.4388 | 0.3615 | 0.4228 | 0.5481 | 1.3258 | 2.5025 | 5.3389 | |
| JNK-IN-5A | JNK | JNK | 1.8491 | 14.2132 | 100.0000 | -0.1818 | 0.1302 | 0.4971 | -0.4099 | 0.0435 | 0.4984 | 0.0000 | 3.1821 | 4.9999 | 0.0989 | 0.2367 | 0.3549 | 1.4898 | 12.5032 | 100.0000 | |
| Everolimus | MTOR | MTOR | 0.0432 | 0.6717 | 4.3873 | -0.8294 | -0.6714 | -0.2303 | -1.0000 | -1.0000 | -0.6838 | 0.2890 | 0.4230 | 0.7677 | 0.3295 | 0.4415 | 0.5925 | 1.5205 | 9.7227 | 26.2255 | |
| Lapatinib | EGFR/HER2 | ErbB | 31.2806 | 100.0000 | 100.0000 | 0.4954 | 0.7950 | 0.9113 | 0.2428 | 0.7519 | 0.9066 | 0.0000 | 0.2457 | 1.3492 | 0.0247 | 0.0703 | 0.1302 | 1.5972 | 63.5403 | 100.0000 | |
| Oxamflatin | HDAC | HDAC | 0.6664 | 0.9513 | 1.6592 | -0.9525 | -0.8858 | -0.8199 | -1.0000 | -0.9857 | -0.8929 | 1.0334 | 1.2610 | 1.4776 | 0.4375 | 0.5175 | 0.6006 | 1.6681 | 2.6703 | 3.8183 | |
| Bosutinib | Src | nRTK | 1.2187 | 1.7497 | 4.1420 | -0.6727 | -0.4219 | -0.1512 | -0.7662 | -0.4684 | -0.1288 | 0.9612 | 1.6575 | 1.9534 | 0.3079 | 0.3819 | 0.4639 | 1.7722 | 2.5602 | 5.3523 | |
| NSC 663284 | CDC25 | CDC | 1.6689 | 2.2519 | 3.0742 | -0.9668 | -0.9336 | -0.8607 | -0.9846 | -0.9413 | -0.8554 | 1.8405 | 2.5456 | 4.2988 | 0.5484 | 0.5805 | 0.6318 | 2.2603 | 3.4718 | 5.7633 | |
| Glycyl-H-1152 | ROCK2 | N/A | 7.8389 | 29.5632 | 100.0000 | 0.0725 | 0.4318 | 0.6407 | -0.4259 | 0.0666 | 0.6245 | 0.3449 | 0.9010 | 2.0476 | 0.0704 | 0.1476 | 0.1891 | 2.5420 | 16.8696 | 100.0000 | |
| TPCA-1 | IKK | NFKB | 4.9121 | 23.5816 | 100.0000 | 0.0988 | 0.4346 | 0.6277 | -0.1071 | 0.3912 | 0.5674 | 0.5796 | 1.2158 | 2.2892 | 0.0966 | 0.1616 | 0.2244 | 2.5700 | 5.7466 | 43.2238 | |
| GSK1838705A | IGF1R | RTK | 4.0665 | 10.9435 | 23.1329 | -0.6969 | -0.3849 | -0.1067 | -0.7773 | -0.4275 | -0.2150 | 1.5275 | 2.6721 | 3.2208 | 0.2264 | 0.2964 | 0.4149 | 2.6121 | 7.6760 | 17.5013 | |
| IKK16 | IKK | NFKB | 1.8767 | 3.1049 | 3.8519 | -0.9668 | -0.9445 | -0.8619 | -0.9890 | -0.9578 | -0.8641 | 2.2018 | 3.4729 | 4.3592 | 0.3739 | 0.4332 | 0.4763 | 3.1521 | 4.0389 | 4.8853 | |
| GSK1070916 | AURK | AURK | 0.6046 | 3.0981 | 6.6549 | -0.8474 | -0.6391 | -0.3610 | -1.0000 | -1.0000 | -0.9999 | 0.6499 | 0.9902 | 1.5949 | 0.2113 | 0.2924 | 0.4314 | 3.5405 | 8.2453 | 15.6107 | |
| AG1478 | EGFR | ErbB | 8.7673 | 51.6075 | 100.0000 | -0.0710 | 0.2684 | 0.6341 | -0.3109 | -0.0273 | 0.4206 | 0.8939 | 1.7205 | 2.6373 | 0.0902 | 0.1531 | 0.2936 | 3.7212 | 36.6666 | 94.4655 | |
| Cetuximab | EGFR | ErbB | 100.0000 | 100.0000 | 100.0000 | 0.7284 | 0.8755 | 0.9754 | 0.5964 | 0.8555 | 0.9754 | 0.0000 | 0.0000 | 0.7916 | -0.0099 | 0.0234 | 0.0674 | 3.7461 | 100.0000 | 100.0000 | |
| Etoposide | TOP2 | TOP | 1.1610 | 2.9708 | 7.6285 | -0.6938 | -0.4841 | -0.2079 | -0.7406 | -0.5842 | -0.4690 | 0.5531 | 0.8108 | 1.2247 | 0.3770 | 0.4769 | 0.5711 | 4.4274 | 7.6731 | 19.6965 |